Figure 4. Expression pattern of miR-503-5p in macrophage-EVs in the context of atherosclerosis. PMA-induced THP-1 and RAW264.7 cells were treated with ox-LDL at doses of 25 μg/mL, 50 μg/mL and 100 μg/mL, respectively. (A) Foam cells (×200) in PMA-induced THP-1 and RAW264.7 cells detected by Oil red O staining. (B) Expression of miR-503-5p (normalized to U6) in PMA-induced THP-1 with or without ox-LDL treatment and their derived EVs determined by RT-qPCR. (C) Expression of miR-503-5p (normalized to U6) in PMA-induced RAW264.7 cells with or without ox-LDL treatment and their derived EVs determined RT-qPCR. (D) The expression of miR-503-5p (normalized to U6) in plasma-EVs of healthy individuals (n = 30) and patients with atherosclerosis (n = 53) determined by RT-qPCR. Values obtained from three independent experiments in triplicate were analyzed by unpaired t test between two groups and by one-way ANOVA followed by Tukey's post hoc test among three or more groups. *p < 0.05 compared with healthy individuals or PMA-induced THP-1 or RAW264.7 cells without ox-LDL treatment.